• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A型肉毒杆菌毒素100单位与200单位治疗难治性特发性膀胱过度活动症的疗效比较

Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.

作者信息

Abdelwahab Osama, Sherif Hammouda, Soliman Tark, Elbarky Ihab, Eshazly Aly

机构信息

Urology department, Faculty of Medicine, Benha University, Egypt.

出版信息

Int Braz J Urol. 2015 Nov-Dec;41(6):1132-40. doi: 10.1590/S1677-5538.IBJU.2014.0221.

DOI:10.1590/S1677-5538.IBJU.2014.0221
PMID:26742971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4756939/
Abstract

OBJECTIVE

To evaluate the efficacy and safety of a single intra detrusor injection of BoNTA comparing two different doses (100 U or 200 U) in patients with idiopathic overactive bladder.

MATERIALS AND METHODS

A randomized prospective study evaluated the efficacy of BoNTA in management of refractory idiopathic overactive bladder and included 80 patients. All patients were assessed initially by taking a history, a physical examination, overactive bladder symptom score, urine analysis, routine laboratory investigations, KUB and pelviabdominal. OABSS was adjusted on all patients postoperative at 1,3,6,9 months also Urodynamic was done for all patients preoperative and postoperative at 3, 6, 9 months.

RESULTS

The mean age was 30.22±8.37 and 31.35±7.61 in group I and II respectively. There was no statistically difference between both groups in all parameters all over the study except at 9 months after treatment. Hematuria was observed 6 and 9 patients in group I and II respectively. Dysuria was observed in 6 and 15 patients in group I and II respectively. UTI was detected in 3 and 7 patients in group I and II respectively.

CONCLUSION

A single-injection procedure of 100 U or 200 U BoNTA is an effective and safe treatment for patients with IOAB who failed anticholinergic regimens. OABSS and QoL were improved for 6 months; 100 U injections seemed to have comparable results with 200 U. There was a significant difference at month 9 towards 200 U with more incidences of adverse events.

摘要

目的

评估在特发性膀胱过度活动症患者中单次膀胱逼尿肌注射两种不同剂量(100 U或200 U)肉毒杆菌毒素A(BoNTA)的疗效和安全性。

材料与方法

一项随机前瞻性研究评估了BoNTA治疗难治性特发性膀胱过度活动症的疗效,纳入80例患者。所有患者最初均通过病史采集、体格检查、膀胱过度活动症症状评分、尿液分析、常规实验室检查、腹部平片及盆腔腹部检查进行评估。所有患者在术后1、3、6、9个月时调整膀胱过度活动症症状评分,并且所有患者在术前及术后3、6、9个月时进行尿动力学检查。

结果

第一组和第二组的平均年龄分别为30.22±8.37和31.35±7.61。在整个研究过程中,除治疗后9个月外,两组在所有参数上均无统计学差异。第一组和第二组分别有6例和9例患者出现血尿。第一组和第二组分别有6例和15例患者出现排尿困难。第一组和第二组分别有3例和7例患者检测出尿路感染。

结论

对于抗胆碱能治疗方案失败的特发性膀胱过度活动症患者,单次注射100 U或200 U BoNTA是一种有效且安全的治疗方法。膀胱过度活动症症状评分和生活质量在6个月内得到改善;100 U注射似乎与200 U注射效果相当。在第9个月时,200 U注射组出现更多不良事件,差异有统计学意义。

相似文献

1
Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.A型肉毒杆菌毒素100单位与200单位治疗难治性特发性膀胱过度活动症的疗效比较
Int Braz J Urol. 2015 Nov-Dec;41(6):1132-40. doi: 10.1590/S1677-5538.IBJU.2014.0221.
2
[INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].A型肉毒毒素注射于无逼尿肌过度活动的膀胱过度活动症患者的膀胱逼尿肌和黏膜下层
Urologiia. 2015 Mar-Apr(2):31-4.
3
The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.在慢性脊髓损伤患者中,重复使用 200 或 300 单位的肉毒毒素 A 进行膀胱内注射的治疗效果。
Neurourol Urodyn. 2014 Jan;33(1):129-34. doi: 10.1002/nau.22395. Epub 2013 Mar 12.
4
Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.低剂量肉毒毒素 A 治疗难治性特发性逼尿肌过度活动症的疗效和安全性:一项多中心、双盲、随机、安慰剂对照剂量范围研究。
Eur Urol. 2012 Mar;61(3):520-9. doi: 10.1016/j.eururo.2011.10.028. Epub 2011 Oct 25.
5
Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.膀胱基底部/三角区注射与膀胱体注射奥昔布宁治疗抗毒蕈碱药物难治性特发性逼尿肌过度活动症一样安全有效。
Neurourol Urodyn. 2011 Sep;30(7):1242-8. doi: 10.1002/nau.21054. Epub 2011 May 10.
6
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.肉毒杆菌毒素 A 100U 显著改善伴有尿急和尿失禁的膀胱过度活动症患者的所有特发性膀胱过度活动症症状和生活质量:一项随机、双盲、安慰剂对照试验。
Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.
7
Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.膀胱内注射肉毒杆菌毒素后特发性逼尿肌过度活动患儿的客观和主观改善:初步报告。
J Pediatr Surg. 2019 Mar;54(3):595-599. doi: 10.1016/j.jpedsurg.2018.05.012. Epub 2018 May 21.
8
Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.膀胱内注射肉毒毒素 A 治疗特发性逼尿肌过度活动的不良反应:危险因素及对治疗效果的影响。
Eur Urol. 2010 Dec;58(6):919-26. doi: 10.1016/j.eururo.2010.09.007. Epub 2010 Sep 17.
9
Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.对100例抗胆碱能药物难治性特发性膀胱过度活动症患者进行肉毒杆菌A毒素膀胱逼尿肌注射治疗的经验。
J Urol. 2006 Jul;176(1):177-85. doi: 10.1016/S0022-5347(06)00590-8.
10
Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.难治性特发性膀胱过度活动症的治疗:膀胱逼尿肌内注射A型肉毒杆菌毒素与胫后神经刺激术的比较
Can J Urol. 2017 Jun;24(3):8838-8846.

引用本文的文献

1
Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research.用于特发性膀胱过度活动症的膀胱内注射A型肉毒杆菌毒素方案:临床结果、技术以及对实践和未来研究的影响的范围综述
Toxins (Basel). 2025 Apr 23;17(5):211. doi: 10.3390/toxins17050211.
2
Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.膀胱内注射肉毒毒素 A 治疗特发性逼尿肌过度活动症或神经源性逼尿肌过度活动患者的不良反应:一项随机对照研究的系统评价和荟萃分析。
Toxins (Basel). 2024 Aug 5;16(8):343. doi: 10.3390/toxins16080343.
3
Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery.A 型肉毒毒素膀胱内注射治疗非膀胱出口梗阻男性患者和前列腺手术后再梗阻。
Toxins (Basel). 2023 Mar 15;15(3):221. doi: 10.3390/toxins15030221.
4
Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.预测女性非神经源性急迫性尿失禁经尿道内注射肉毒毒素 A 后的结局。
Neurourol Urodyn. 2022 Jan;41(1):432-447. doi: 10.1002/nau.24845. Epub 2021 Dec 2.
5
Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology.随机临床试验评估治疗非神经源性膀胱过度活动症的三线治疗方法:方法学综述。
Int Urogynecol J. 2021 Oct;32(10):2603-2618. doi: 10.1007/s00192-021-04688-z. Epub 2021 Mar 26.
6
Comparison of 100 U With 200 U of Intradetrusor OnabotulinumToxinA for Nonneurogenic Urgency Incontinence.100U 与 200U 经尿道注射 A 型肉毒毒素治疗非神经源性急迫性尿失禁的比较
Female Pelvic Med Reconstr Surg. 2021 Mar 1;27(3):140-146. doi: 10.1097/SPV.0000000000001020.
7
Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder.使用不同剂量A型肉毒杆菌毒素治疗膀胱过度活动症患者尿失禁的随机对照试验的Meta分析
Front Pharmacol. 2020 Jan 15;10:1618. doi: 10.3389/fphar.2019.01618. eCollection 2019.
8
A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.不同剂量A型肉毒毒素治疗膀胱过度活动症有效性和安全性的系统评价与Meta分析
Oncotarget. 2017 Aug 7;8(52):90338-90350. doi: 10.18632/oncotarget.20056. eCollection 2017 Oct 27.
9
RE: Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.关于:A型肉毒杆菌毒素100单位与200单位治疗难治性特发性膀胱过度活动症的疗效比较
Int Braz J Urol. 2016 Mar-Apr;42(2):399. doi: 10.1590/S1677-5538.IBJU.2015.0726.

本文引用的文献

1
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.肉毒杆菌毒素 A 100U 显著改善伴有尿急和尿失禁的膀胱过度活动症患者的所有特发性膀胱过度活动症症状和生活质量:一项随机、双盲、安慰剂对照试验。
Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.
2
Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.循证综述和评估肉毒杆菌神经毒素在治疗泌尿系统疾病中的应用。
Toxicon. 2013 Jun 1;67:129-40. doi: 10.1016/j.toxicon.2013.01.020. Epub 2013 Feb 13.
3
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.肉毒杆菌毒素 A 治疗膀胱过度活动症伴尿失禁患者:一项 3 期、随机、安慰剂对照试验的结果。
J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.
4
Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.抗胆碱能治疗与肉毒毒素 A 治疗急迫性尿失禁。
N Engl J Med. 2012 Nov 8;367(19):1803-13. doi: 10.1056/NEJMoa1208872. Epub 2012 Oct 4.
5
Botulinum toxin for the lower urinary tract.肉毒毒素在泌尿系统中的应用。
BJU Int. 2010 Apr;105(8):1046-58. doi: 10.1111/j.1464-410x.2010.09317.x.
6
Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).肉毒杆菌毒素 A 与安慰剂治疗女性难治性逼尿肌过度活动症的随机双盲安慰剂对照研究:240 名女性参与(RELAX 研究)。
Eur Urol. 2012 Sep;62(3):507-14. doi: 10.1016/j.eururo.2011.12.056. Epub 2012 Jan 5.
7
Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.低剂量肉毒毒素 A 治疗难治性特发性逼尿肌过度活动症的疗效和安全性:一项多中心、双盲、随机、安慰剂对照剂量范围研究。
Eur Urol. 2012 Mar;61(3):520-9. doi: 10.1016/j.eururo.2011.10.028. Epub 2011 Oct 25.
8
Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).当代 A 型肉毒毒素治疗下尿路疾病的管理:肉毒素(保妥适)和注射用 A 型肉毒毒素(丽舒妥)的系统评价。
Eur Urol. 2011 Oct;60(4):784-95. doi: 10.1016/j.eururo.2011.07.001. Epub 2011 Jul 13.
9
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.经头对头、双盲、安慰剂对照、随机、剂量范围研究,评价特利加压素治疗特发性过度活动膀胱的有效性和安全性。
J Urol. 2010 Dec;184(6):2416-22. doi: 10.1016/j.juro.2010.08.021. Epub 2010 Oct 16.
10
Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.膀胱内注射肉毒毒素 A 治疗特发性逼尿肌过度活动的不良反应:危险因素及对治疗效果的影响。
Eur Urol. 2010 Dec;58(6):919-26. doi: 10.1016/j.eururo.2010.09.007. Epub 2010 Sep 17.